Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.
Latest Ratings for MYGN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2021 | SVB Leerink | Maintains | Market Perform | |
| Jun 2021 | Raymond James | Initiates Coverage On | Market Perform | |
| Jun 2021 | Goldman Sachs | Initiates Coverage On | Sell |
